A sexual sporogonic mosquito transmission blocking vaccine (SSM-TBV) against malaria aims to block transmission of malaria from mosquitoes to humans by inducing immunity against the mosquito stages of the parasite, and consequently preventing the parasite from developing into the mosquito. TBVs against the major species of human malaria, Plasmodium falciparum, are under development. The primary goal of a TBV is to provide an additional tool to the global effort of malaria elimination through blocking transmission of malaria parasites in vaccinated areas.

In 2011, the PATH Malaria Vaccine Initiative (MVI) set up a working group dedicated to developing a strategy to inform long-term planning towards clinical development of a TBV, and to obtain licensure for TBVs. To this end, two technical consulting groups were commissioned, one of which worked on a full classical clinical/regulatory pathway, including a phase I / phase II plan followed by a large scale population based phase III trial evaluating efficacy against infection and clinical endpoints before licensure.

AMP supported MVI with the scientific secretariat of the technical consulting group to organize its work, provided expertise within the expert group, and led the development of a technical report and scientific manuscript based on the outcomes of the technical consulting group.